Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Q Salako

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Anticancer Research|May 1, 1997
Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancerS J Denardo, C M Richman, D S Goldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphomaG L DeNardo, S J DeNardo, D S Goldstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenograftsG L DeNardo, L A Kroger, C F Meares, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 1998
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenograftsS J DeNardo, D L Kukis, L A Miers, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 1999
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphomaS J DeNardo, G L DeNardo, D L Kukis, et al.
Anticancer Research|August 26, 1998
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot studyG L Denardo, S J Denardo, D L Kukis, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Anticancer Research|May 1, 1997
Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancerS J Denardo, C M Richman, D S Goldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphomaG L DeNardo, S J DeNardo, D S Goldstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenograftsG L DeNardo, L A Kroger, C F Meares, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 1998
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenograftsS J DeNardo, D L Kukis, L A Miers, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 1999
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphomaS J DeNardo, G L DeNardo, D L Kukis, et al.
Anticancer Research|August 26, 1998
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot studyG L Denardo, S J Denardo, D L Kukis, et al.
Pageof 2